Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P210005/S010

IC-8 Apthera Intraocular Lens (IOL)

Acu Focus, Inc. · Decision date Jul 14, 2026

FDA DECISIONP210005/S010

What did the FDA approve?

FDA records P210005/S010 as a supplement to PMA P210005, with the supplement type “Normal 180 Day Track No User Fee”. The recorded decision is approval, dated Jul 14, 2026.

FDA approval order statement

approval for continuing to conduct the PAS2 study under the currently approved protocol, SAIL-101-PAS2 Protocol Version 3.2, as approved under P210005/S004
Regulatory pathway
PMA supplement
Supplement type
Normal 180 Day Track No User Fee
Clinical specialty
Ophthalmic
Decision date
Jul 14, 2026
FDA change category
Postapproval Study Protocol

FDA source record

Regulatory record facts

Identifier
P210005/S010
Regulatory pathway
PMA supplement
Product code
POE
Decision code
APPR
Decision date
Jul 14, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Extended depth of focus intraocular lens.

Product code
POE
FDA device class
3

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P210005/S010 received

    Application receipt date recorded by FDA.

  2. P210005/S011 · Related supplement

    IC-8 Apthera Intraocular Lens (IOL)

  3. P210005/S010 · FDA decision

    Normal 180 Day Track No User Fee

Timeline entries are records held by MedtechLedger for P210005. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P210005

Product / regulatory recordCompanyPathwayDecision dateSource
Acu Focus, Inc.PMA supplementAug 4, 2025FDA

Explore the linked device profile

Other records with product code POE

Product / regulatory recordCompanyPathwayDecision dateSource
Alcon Laboratories, LLCPMA supplementOct 30, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Acu Focus, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
32 Discovery Suite 200, Irvine, CA, 92618

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records